/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Preclinical characterisation and first-in-human results on the tolerability and pharmacodynamic effect of REGN9933, a monoclonal antibody targeting the factor XI/activated factor XI apple 2 domain
Event: ESC Congress 2024
Topic: Anticoagulants
Session: Biotherapies in cardiovascular disease: from bench to bedside
